Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains
one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Viral vectors have been used for a broad spectrum of gene therapy for both acute and
chronic diseases. In the context of cancer gene therapy, viral vectors expressing anti-tumor …

Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found
in the central nervous system. Currently, standard treatments in the clinic include maximal …

Surgical resection remains the mainstay of treatment for patients with glioma of any grade.
Maximal resection of the tumour is central to achieving long-term disease control; however …

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic
application is limited by toxic inflammatory responses. We assessed the safety and …